0001178913-23-002227.txt : 20230616
0001178913-23-002227.hdr.sgml : 20230616
20230616160305
ACCESSION NUMBER: 0001178913-23-002227
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230614
FILED AS OF DATE: 20230616
DATE AS OF CHANGE: 20230616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fatal Sigal
CENTRAL INDEX KEY: 0001850994
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38807
FILM NUMBER: 231020894
MAIL ADDRESS:
STREET 1: 16 KANFEY NESHARIM ST.
CITY: RAMAT GAN
STATE: L3
ZIP: 5235716
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd.
CENTRAL INDEX KEY: 0001534248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813676773
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
BUSINESS PHONE: 972-77-331-0156
MAIL ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
FORMER COMPANY:
FORMER CONFORMED NAME: Anchiano Therapeutics Ltd.
DATE OF NAME CHANGE: 20180906
FORMER COMPANY:
FORMER CONFORMED NAME: BioCancell Ltd.
DATE OF NAME CHANGE: 20111104
4
1
ownership.xml
X0407
4
2023-06-14
0
0001534248
Chemomab Therapeutics Ltd.
CMMB
0001850994
Fatal Sigal
16 KANFEY NESHARIM ST.
RAMAT GAN
L3
5235716
ISRAEL
0
1
0
0
Chief Financial Officer
0
American Depositary Shares
5209
D
Option to Purchase American Depositary Shares
1.70
2023-06-14
4
A
0
102860
0
A
2033-06-14
American Depositary Shares
102860
167860
D
Option to Purchase American Depositary Shares
2.11
2022-11-08
4
A
0
29400
0
A
2032-11-08
American Depositary Shares
29400
65000
D
Option to Purchase American Depositary Shares
9.83
2021-11-11
4
A
0
35600
0
A
2031-11-11
American Depositary Shares
35600
35600
D
Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this form 4 for informational purposes only.
Options granted under the Company's 2017 Equity-Based Incentive Plan (the "Plan") on June 14, 2023; 25% of the options vest and become exercisable following 12 months from the grant thereof and an additional 6.25% vests at the end of each calendar quarter thereafter such that the options are fully vested and exercisable on June 14, 2027, subject to acceleration upon a change in control pursuant to the terms of the Option Agreement ("CIC") by and between the Reporting Person and the Issuer and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).
These options vest and become exercisable pursuant to the following schedule: 25% of the options shall vest on November 8, 2023, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).
These options vest and become exercisable pursuant to the following schedule: 25% of the options vested on November 11, 2022, and the remainder shall vest over three years in quarterly equal installments, subject to acceleration upon a change in control pursuant ("CIC") and continued service by the Reporting Person. In addition, following a CIC, the exercise period of the option shall be extended to 12 months following termination of service, other than in the event of termination For Cause (as defined in the Plan).
/s/ David S. Glatt, Attorney-in-Fact for Sigal Fatal
2023-06-16